Target
TROP2
5 products, 5 indications
Indications
NSCLC (2 products)
metastatic non-small cell lung cancer (2 products)
advanced non-squamous NSCLC (1 products)
glioblastoma (1 products)
Metastatic Cancer (1 products)
Loading...
2 drugs
31 abstracts
Abstract
TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) in advanced non-small cell lung cancer (aNSCLC).Org: National Cancer Center Hospital East, Kashiwa, Japan, National Cheng Kung University, Daiichi Sankyo Inc., Taichung Veterans General Hospital, Mayo Clinic,
Abstract
SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer.Org: Dana-Farber Cancer Institute, University of Chicago Medicine, UNC Lineberger Comprehensive Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Emory University Hospital,
Abstract
Sacituzumab tirumotecan (SKB264/MK-2870) in patients (pts) with previously treated locally recurrent or metastatic triple-negative breast cancer (TNBC): Results from the phase III OptiTROP-Breast01 study.Org: Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China, Jiangsu Province Hospital, Nanjing, China, Hunan Cancer Hospital, Changsha, China, Shandong Cancer Hospital and Institute, Jinan, China, Zhejiang Cancer Hospital, Hangzhou, China,
Abstract
A phase II, multicenter, prospective study of sacituzumab govitecan in recurrent glioblastoma.Org: The University of Texas Health Science Center at San Antonio, Texas Oncology in Austin, Mays Cancer Center, UT Health Science Center at San Antonio,
Abstract
Detection of TROP2: Ushering in a new choice in the treatment of patients with special types of invasive breast cancer.Org: Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, The Fourth Hospital of Hebei Medical University, Shijiazhuang Yiling Pharmaceutical, China National Biotec Group,
Abstract
Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Patient-reported outcomes (PROs) from the TROPION-Breast01 study.Org: Institut Català D'Oncologia, IDIBELL, Seoul National University Hospital, Cancer Research Institute, Aichi Cancer Center Hospital,
Abstract
Sacituzumab tirumotecan (SKB264/MK-2870) in combination with KL-A167 (anti-PD-L1) as first-line treatment for patients with advanced NSCLC from the phase II OptiTROP-Lung01 study.Org: Sun Yat-sen University Cancer Center, Henan Cancer Hospital Affiliated Cancer Hospital of Zhengzhou University, Jilin Cancer Hospital, Hunan Cancer Hospital, Affiliated Cancer Hospital of Xiangya School of Medicine,
Abstract
TOPOLOGY: A phase II study to evaluate the efficacy and toxicities of PLX038, in patients with locally advanced or metastatic triple-negative breast cancer.Org: Institut Curie, Saint Cloud, France, Hopital Privé des Cotes d'Armor, Paris and Saint-Cloud, Medical Oncology Department and D3i, Paris and Saint Cloud,
Abstract
Phase I/II study of TROP2 CAR engineered IL15-transduced cord blood-derived NK cells delivered intraperitoneally for the management of platinum resistant ovarian cancer, mesonephric-like adenocarcinoma, and pancreatic cancer.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Department of Investigational Cancer Therapeutics, Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX,
Abstract
SMART: A phase II study of sacituzumab govitecan (SG) with or without atezolizumab immunotherapy in rare genitourinary (GU) tumors such as small cell, adenocarcinoma, and squamous cell bladder/urinary tract cancer, renal medullary carcinoma (RMC) and penile cancer.Org: Genitourinary Malignancies Branch, CCR, NCI, NIH, Bethesda, MD, New York University Grossman School of Medicine, New York, NY, Urologic Oncology Branch, CCR, NCI, NIH, Bethesda, MD, Radiology and Imaging Sciences, CCR, NCI, NIH, Bethesda, MD, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD,
Abstract
A phase III randomized trial of eribulin (E) with gemcitabine (G) vs standard of care (SOC) for patients (pts) with metastatic urothelial carcinoma (mUC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937 updated design.Org: Davis Comprehensive Cancer Center, Swog Gu Bladder Patient Advocate,
Abstract
Analysis of drug-related interstitial lung disease (ILD) inpatients (pts) treated with datopotamab deruxtecan (Dato-DXd).Org: University Hospital of Nantes Medical Oncology,
Abstract
Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy for advanced non-small cell lung cancer (aNSCLC): Subgroup analysis from TROPION-Lung02.Org: CNIO-H12O Lung Cancer Unit, Departamento de Investigacion de Cancer de Pulmon, Hospital Universitario 12 de Octubre, CNIO-H12O Lung Cancer Unit, Department of Oncology, National Cheng Kung University Hospital, Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Università degli Studi di Milano-Bicocca,
Abstract
Novel protein drug conjugate ANXV-chemo and cytotoxic and anti-proliferative effects against human triple-negative breast cancer in vitro.Org: Annexin Pharmaceuticals AB (publ), Truly Labs AB, ALMIR Conseil,
Abstract
Datopotamab deruxtecan (Dato-DXd) in Chinese patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC): Results from the phase 1/2 TROPION-PanTumor02 study.Org: Jiangxi Provincial People's Hospital,
Abstract
Novel TROP2-targeted CAR T cells with high specificity and sustained efficacy for solid tumors in animal models.Org: OBI Pharma, Inc.,
Abstract
Comprehensive analysis of TROP2, PD-L1, stromal (s)TILs, and HER2 expression patterns in patients (pts) with metastatic HR+HER2- breast cancer.Org: Dana-Farber Cancer Institute, University of Milan and European Institute of Oncology, IRCCS, Brigham and Women's Hospital, University of Milano, European Institute of Oncology, Division of Early Drug Development, European Institute of Oncology,
Abstract
A phase II umbrella clinical trial of advanced salivary gland cancer based on molecular typing.Org: Minimally Invasive Therapy Center,
Abstract
Identifying mutations in ctDNA to predict antibody-drug conjugate response in breast cancer.Org: UT Southwestern Medical Center, Dallas, TX,
Abstract
Results of a phase 1/2 study of MHB036C: A potential best-in-class TROP2 antibody-drug conjugate (ADC) incorporating a potent DNA topoisomerase I inhibitor in locally advanced or metastatic solid tumors.Org: Zheijang Cancer Hospital, Department of Oncology, the Second People's Hospital of Yibin, Nanyang First People's Hospital,
Abstract
Trophoblast cell-surface antigen 2 is a biomarker and potential therapeutic target in human colon cancer.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, State Key Laboratory of Systems Medicine for Cancer, Renji Hospital Shanghai Jiaotong University School of Medicine, Shanghai Jiao Tong University School of Medicine, Shanghai, China, Gracell Biotechnologies, Ltd.,
Abstract
Preliminary results from a first-in-human study of ESG401, a trophoblast cell-surface antigen 2 (TROP2) antibody drug conjugate (ADC), in patients with locally advanced/metastatic solid tumors.Org: National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China, Department of Medical Oncology, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China, Tianjin cancer hospital ,China, Tianjin, China, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China,
Abstract
TROPION-PanTumor03: Phase 2, multicenter study of datopotamab deruxtecan (Dato-DXd) as monotherapy and in combination with anticancer agents in patients (pts) with advanced/metastatic solid tumors.Org: Memorial Sloan Kettering Cancer Center, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Hospital Universitari Vall d’Hebron, Vall d’Hebron Institute of Oncology, Vall d’Hebron Barcelona Hospital Campus, University of Wisconsin Carbone Cancer Center,
Abstract
TROPION-Lung04: Phase 1b, multicenter study of datopotamab deruxtecan (Dato-DXd) in combination with immunotherapy ± carboplatin in advanced/metastatic non-small cell lung cancer (mNSCLC).Org: Fox Chase Cancer Center, Washington University School of Medicine in St Louis, University Hospitals Sussex NHS Foundation Trust, Case Comprehensive Cancer Center, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research (JFCR),
Abstract
The genomic, transcriptomic, and immunological landscape of TROP2 in solid tumors.Org: Caris Life Sciences, Irving, TX, Lombardi Comprehensive Cancer Center, Montefiore Einstein Center for Cancer Care, St. John's Cancer Institute, Santa Monica, CA, Penn State Milton S. Hershey Medical Center, Hershey, PA,
Abstract
TROP2 expression and response to immune checkpoint inhibition in patients with advanced non-small cell lung cancer.Org: Early Phase Trials Unit, Institut Bergonié and University of Bordeaux, Bordeaux, France, Institut Bergonié, University of Bordeaux, Bergonié Institute, ImmuSmol,
Abstract
Personalized therapy for head and neck squamous carcinoma (HNSCC) utilizing tissue proteomics profiling.Org: mProbe Inc., Stanford University School of Medicine,
Abstract
SKB264 (TROP2-ADC) for the treatment of patients with advanced NSCLC: Efficacy and safety data from a phase 2 study.Org: Sichuan Kelun-Biotech Biopharmaceutical, Collaborative Innovation Center for Cancer Medicine, Department of Medicine, Division of Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
Therapeutic strategies for metaplastic breast cancer: A clinicopathologic analysis of a single institution cohort.Org: University of California San Diego Medical Center, La Jolla, CA, UC San Diego Moores Cancer Center,
Abstract
Real-world use, dose intensity, and adherence to enfortumab vedotin (EV) in locally advanced or metastatic urothelial cancer (la/mUC).Org: Astellas Pharma Inc., Astellas Pharma, Abramson Cancer Center,
Drug
tusamitamab